false
Catalog
2023 World Conference on Lung Cancer (Posters)
EP08.02. Neoadjuvant Therapy, Still a Contraindica ...
EP08.02. Neoadjuvant Therapy, Still a Contraindication to VATS Lobectomy or is it a New Indication? - PDF(Abstract)
Back to course
Pdf Summary
This study aimed to evaluate the feasibility, safety, and outcomes of video-assisted thoracoscopy (VATS) in patients with non-small cell lung cancer (NSCLC) who received neoadjuvant therapy (NT). VATS has become the preferred surgical technique for resectable early-stage NSCLC due to its faster recovery, lower pain, and aesthetically pleasing results. However, VATS is considered a relative contraindication in patients who have received neoadjuvant therapy traditionally. This study aimed to assess whether neoadjuvant therapy could increase the frequency of VATS application by reducing tumor stage and diameter.<br /><br />The data of patients who underwent VATS lung resection and lymph node dissection for NSCLC between 2011 and 2021 were analyzed. The patients were divided into two groups: Group 1 included patients who did not receive oncological treatment before surgery, and Group 2 included patients who received neoadjuvant treatment before surgery. Surgical details, postoperative complications, and pathological stages were compared between the two groups.<br /><br />A total of 306 patients were included in the study, with Group 1 comprising 236 patients and Group 2 comprising 70 patients. Complications were observed in 33% of patients after surgery, with no significant difference between the two groups. Mortality was detected in 1.6% of patients, again with no significant difference between the groups. The mean operation time was slightly longer in Group 2. Conversion to thoracotomy occurred in 17% of Group 1 patients and 25% of Group 2 patients. Distant metastasis and local recurrence were observed in both groups, with a slightly higher prevalence in Group 2.<br /><br />The results of this study suggest that VATS can be safely performed in patients who have received neoadjuvant therapy, with similar oncological outcomes. Neoadjuvant therapy may also decrease tumor size and increase the frequency of VATS application. Thus, neoadjuvant therapy could be considered a new indication for VATS in NSCLC patients. Further research is needed to confirm these findings and explore the potential benefits of neoadjuvant therapy in VATS procedures.
Asset Subtitle
Cengiz Gebitekin
Meta Tag
Speaker
Cengiz Gebitekin
Topic
Local-Regional NSCLC: Multimodality Therapy
Keywords
video-assisted thoracoscopy
VATS
non-small cell lung cancer
NSCLC
neoadjuvant therapy
feasibility
safety
oncological treatment
tumor stage
surgical technique
×
Please select your language
1
English